
    
      The objectives of the study were to confirm the safety and to test the efficacy of 3,4-DAP in
      the treatment of LEMS-related weakness.

      This was a phase 2 randomized double-blind placebo-controlled withdrawal study in subjects
      with known clinically active LEMS who had been on a chronic stable dose of compassionate
      distribution Jacobus 3,4-DAP provided through FDA-approved individual investigator-held INDs.
    
  